Current and emerging treatment options for myopic choroidal neovascularization

Current and emerging treatment options for myopic choroidal neovascularization

Blog Article

Leila El Matri, Ahmed Chebil, Fedra Dressings Kort Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Faculty of Medicine of Tunis, University of El Manar, Tunis, Tunisia Abstract: Choroidal neovascularization (CNV) is the main cause of visual impairment in highly myopic patients younger than 50 years of age.There are different treatments for myopic CNV (mCNV), with 5- to 10-year outcomes currently.Chorioretinal atrophy is still the most important determinant factor for Outdoor Games - Games visual outcome.

The purpose of this study is to provide an overview of the current treatments for mCNV, including laser, surgical management, verteporfin photodynamic therapy, and mainly anti-vascular endothelial growth factor therapy.Emerging treatment options are also discussed.Keywords: myopia, choroidal neovascularization, current treatment, emerging treatment.